Arthneeti
Latest: Windlas Biotech Ltd Q1 FY27 (Apr–Jun 2026) results →This page is Q3 FY26 (Oct–Dec 2025).All Q3 FY26 results →
WB

Windlas Biotech Ltd

Q3 FY26Pharmaceuticals & Biotechnology

Windlas Biotech Q3 FY26 earnings call: Revenue & Margins

Q3 FY26 earnings call: what management said on revenue, margins and capex.

Price₹994
Market cap₹2.0K Cr
P/E29.5
Updated23 Aug 2026
Read4 min read

The short version

The management refrains from giving specific future quantitative guidance on revenue, earnings, or EPS, emphasizing focus on disciplined execution and long-term strategy.

From Windlas Biotech Ltd's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

  • The company aims to continuously increase its customer base, product portfolio, and business development efforts.
  • Investment in new plants (e.g., Plant 6) and expansions (injectables, oral solids) are expected to support growth, with Plant 6 commercialization anticipated in H1 FY '27.
  • Management stresses the importance of disciplined execution, capability building, and operational excellence to drive sustainable growth.
  • Trade Generics segment shows long-term growth potential (~40% CAGR historically), though quarterly growth rates have varied due to competitive intensity and lumpiness of institutional orders.

2 more points from Windlas Biotech Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Windlas Biotech Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • Plant 6 is nearing mechanical completion by end of FY '26, with expected capex around INR 50-60 crores; most of this capex is already incurred, with about INR 10 crores remaining.
  • Maintenance capex continues at approximately INR 15 crores.
  • Plant 6 will add capacity to reach about INR 1,000 crores revenue (excluding injectables), and injectables contribute an additional INR 100 crores capacity.
  • Future capex will follow business needs and capacity utilization; expansions will be made as required.
  • Plans include either acquiring strategic opportunities or investing in new dosage forms once injectable utilization approaches capacity.

2 more points from Windlas Biotech Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
1KRM Ayurveda
Rev 1Mar 1
2Accretion Pha.
Rev 1Mar 2
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Windlas Biotech Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

  • Windlas Biotech mentioned lumpiness in institutional orders affecting quarterly Trade Generics growth.
  • Some major institutional tenders/orders may slip into subsequent quarters due to timing and execution factors.
  • The company focuses on execution and relationship-building to manage order flow.

2 more points from Windlas Biotech Ltd's call on order book

Create a free account to keep reading this call

Windlas Biotech Ltd — Quarterly revenue & net profit

Revenue Net profit
Dec 2024Q3 FY25
Mar 2025Q4 FY25
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26

Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹238 Cr, net profit ₹16 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Continue your research

What Windlas Biotech's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • Natural Capsules (Q3 FY26)

    Q3FY26 revenue from operations: ₹37.75 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q3 FY26 investor presentation — and how it ranks

  • Wanbury (Q3 FY26)

    Q3FY26 Revenue from Operations: ₹162.45 Crore . Key investor presentation takeaways from Wanbury Ltd's Q3 FY26 investor presentation — and how it ranks against

  • Guj. Themis Bio. (Q3 FY26)

    43.37 crore, up 9.74% YoY from Rs. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q3 FY26 investor presentation — and how it ranks against

  • Balaxi Pharma (Q3 FY26)

    Q3 FY26 revenue: ₹72.54 crore, down marginally by 1% YoY from ₹73.29 crore in Q3 FY25 (Page 19). Key investor presentation takeaways from Balaxi Pharma's Q3 FY2

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharma.

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Windlas Biotech Ltd and 15K+ more earnings calls,
for less than your morning chai

a day

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Windlas Biotech Ltd Q3 FY26 results?

The management refrains from giving specific future quantitative guidance on revenue, earnings, or EPS, emphasizing focus on disciplined execution and long-term strategy.

What is Windlas Biotech Ltd share price analysis?

Windlas Biotech Ltd currently shows a neutral. The stock trades at a P/E of 29.5 with a market cap of ₹1,959 Cr. Investors should review the full earnings analysis for detailed insights.

Is Windlas Biotech Ltd planning capital expenditure?

Plant 6 is nearing mechanical completion by end of FY '26, with expected capex around INR 50-60 crores; most of this capex is already incurred, with about INR 10 crores remaining. - Maintenance capex continues at approximately INR 15 crores. - Plant 6 will add capacity to reach about INR 1,000 crores revenue (excluding injectables), and injectables contribute an additional INR 100 crores capacity. - Future capex will follow business needs and capacity utilization; expansions will be made as required. - Plans include either acquiring strategic opportunities or investing in new dosage forms once injectable utilization approaches capacity. - No current plans for U.S.

Keep Windlas Biotech Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.